Emerging Biologics in Severe Asthma.

Emerging Biologics in Severe Asthma.

Immunol Allergy Clin North Am. 2016 Aug;36(3):609-23

Authors: Pavord ID, Hilvering B, Shrimanker R

Abstract
Asthma is a heterogeneous disease that can be classified into different clinical endotypes, depending on the type of airway inflammation, clinical severity, and response to treatment. This article focuses on the eosinophilic endotype of asthma, which is defined by the central role that eosinophils play in the pathophysiology of the condition. It is characterized by persistently elevated sputum and/or blood eosinophils and by a significant response to treatments that suppress eosinophilia. Eosinophil activity in the airway may be more important than their numbers and this needs to be investigated. Transcriplomic or Metabolomic signatures may also be useful to identify this endotype.

PMID: 27401629 [PubMed - in process]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/29ESMMW
via IFTTT